Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	6/16/2003 8:17:16 PM
From: scaram(o)uche	of 4974

Amylin Pharmaceuticals, Inc. Announces Offering of Convertible Senior Notes Monday June 16, 5:19 pm ET SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN - News) announced today that it intends to offer $150,000,000 of convertible senior notes for sale in a private placement. The offering will be made pursuant to an exemption from registration under the Securities Act of 1933, as amended (the "Securities Act"). It is expected that the convertible senior notes will be due in 2008. Amylin intends to use the net proceeds of this offering for research and development, the planned commercialization of SYMLIN® pending regulatory approvals, and general corporate purposes, including the potential repayment of all or a portion of its outstanding indebtedness to Johnson & Johnson. Amylin may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies, although it currently has not entered into any agreement relating to any such transaction. (snip)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next